The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director

Thursday, August 7, 2008 General News J E 4
DOYLESTOWN, Pa., Aug. 6 The Quigley Corporation(Nasdaq: QGLY) today announced that Gerard M. Gleeson has been named tosucceed George J. Longo, who will be retiring from the Company on September 5,2008, as Vice President, Chief Financial Officer and as a member of the Boardof Directors. Mr. Gleeson joined The Quigley Corporation in 1998 and hasserved in management positions including Corporate Controller of the Companysince 2004.

Mr. Gleeson is a Fellow of the Association of Chartered CertifiedAccountants, the global body of professional accountants, with extensivebusiness and industry acumen that includes tenure as Chief Financial Officerin Ireland for a subsidiary of Allergan Inc., a multi-national pharmaceuticalcompany. Additionally, Mr. Gleeson has senior financial management experiencein the retail and service industries.

Guy J. Quigley, Chairman, President and Chief Executive Officer said,"George Longo has served as CFO and a Director of the Company since 1997 andplayed a vital role in The Quigley Corporation's successes throughout theyears. We are sorry to see him leave and appreciate all of his contributionsto the Company and wish him well in his retirement."

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, is adiversified natural health medical science company. Its Cold Remedy segmentis a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges,gums and sugar free tablets clinically proven to cut the common cold nearly inhalf. COLD-EEZE customers include leading national wholesalers anddistributors, as well as independent and chain food, drug and mass merchandisestores and pharmacies. The Quigley Corporation has wholly owned subsidiaries;Quigley Manufacturing Inc. consists of two FDA approved facilities tomanufacture COLD- EEZE(R) lozenges as well as fulfill other contractmanufacturing opportunities and Quigley Pharma Inc.( conducts research in order to develop andcommercialize a pipeline of patented botanical and naturally derived potentialprescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements"within the meaning of the Private Securities Litigation Reform Act of 1995 andinvolve known and unknown risk, uncertainties and other factors that may causethe Company's actual performance or achievements to be materially differentfrom the results, performance or achievements expressed or implied by theforward-looking statement. Factors that impact such forward-looking statementsinclude, among others, changes in worldwide general economic conditions,changes in interest rates, government regulations, and worldwide competition.CONTACT: George J. Longo Carl Hymans Vice President, CFO G.S. Schwartz & Co. (215) 345-0919 (212) 725-4500

SOURCE The Quigley Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Symmetry Medical Reports Record Second Quarter 200...
EntreMed Reports Second Quarter 2008 Financial Res...